LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

This Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of the tumor to grow and spread. LB-100 has been shown to make anticancer drugs work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein increases the stress signals for the tumor cells that express PP2A. G

Trial Details

NCT ID

NCT06012734

Phase

PHASE1

Sponsor

The Netherlands Cancer Institute

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• LB-100
• Atezolizumab

Locations (sample)

• Amsterdam, North Holland, Netherlands|52.37403,4.88969

Key Eligibility Criteria

• Signed Informed Consent Form (ICF);
• Age ≥ 18 years at time of signing ICF;
• Ability to comply with the study protocol;
• Histological or cytological confirmed colorectal cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →